Willis Towers Watson Public WTW
- Market cap
- $30.1B
- PE
- 19.9×
- 10y median 26.0×
- Forward PE
- 15.5×
- 10y median 17.1×
- Price to sales
- 3.0×
- EV/EBIT
- 15.4×
- Revenue, 12 months
- $10.1B
- +3% on a year ago
- Net margin
- 15.5%
- Free cash flow yield
- 5.6%
Willis Towers Watson Public trades at 19.9× trailing earnings, cheaper than 74% of the last ten years. Revenue was $10.1B over the last twelve months, up 3% on a year earlier with a 15% net margin.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $2.2B+11% | $2.9B+7% | $2.3B+4% | $2.3B+5% | $2.3B+6% | $3B+4% | $2.2B−5% | $2.3B−0% | $2.3B+0% | $2.9B−3% | $2.4B+9% | $2.5B+9% | |
| $159M+3% | $779M+10% | $280M−2% | $212M+49% | −$766M | $901M+16% | $432M+54% | $368M+74% | $418M | $1B+13% | $448M+4% | $364M−1% | |
| Interest expense | $61M+13% | $63M+17% | $64M+19% | $68M+19% | $65M+7% | $66M+5% | $65M+2% | $64M−6% | $65M+0% | $66M+0% | $77M+19% | $78M+22% |
| Pre-tax income | $164M−11% | $739M+0% | $242M−6% | $167M+39% | −$2B | $1.7B+129% | $303M+25% | $313M+87% | $390M | $947M−44% | $376M+24% | $292M−7% |
| $25M+2400% | $116M−12% | $48M−4% | $26M+8% | −$322M | $440M+279% | $65M+35% | −$21M | $77M | $197M−55% | $70M+8% | $57M | |
| Net income | $136M−28% | $622M+6% | $190M−6% | $141M+50% | −$1.7B | $1.2B+100% | $235M+24% | $331M+135% | $304M | $735M−41% | $297M+26% | $229M−31% |
| $1.29−25% | $6.04+9% | $1.83−3% | $1.36+55% | −$16.44 | $12.59+108% | $2.33+27% | $3.32+144% | $3.11 | $7.66−39% | $3.10+33% | $2.43−27% | |
| 105M−5% | 103M−3% | 104M−4% | 103M−4% | 102M−3% | 99M−4% | 101M−3% | 100M−3% | 98M−4% | 96M−3% | 96M−5% | 94M−6% |
EPS, diluted: 7 periods, Q4 FY10 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: Q2 FY09: not printed by the filing, worked out from its own lines. 12 periods, Q4 FY10 to Q4 FY25: share-days: the 12-month average less the 9-month, weighted by days. Q4 FY12 and Q4 FY15: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days. Q4 FY18 and Q4 FY21: the earlier year to date counted no dilution: the quarter's basic count plus the later year to date's dilution.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Estimates
Next earnings report: .
| Quarter | Revenue | Range | EPS | Range | Analysts |
|---|---|---|---|---|---|
| Q3 FY26 | $2.5B | $2.4B to $2.5B | $3.59 | $3.45 to $3.80 | 14 |
| Q4 FY26 | $3.1B | $3.1B to $3.2B | $9.17 | $9.06 to $9.37 | 13 |
| Q1 FY27 | $2.5B | $2.5B to $2.6B | $4.26 | $4.01 to $4.53 | 12 |
| Q2 FY27 | $2.6B | $2.5B to $2.6B | $3.83 | $3.77 to $3.91 | 5 |
| Q3 FY27 | $2.6B | $2.6B to $2.6B | $4.34 | $4.27 to $4.44 | 5 |
| Q4 FY27 | $3.3B | $3.2B to $3.3B | $10.49 | $10.32 to $10.72 | 5 |
| Q1 FY28 | $2.7B | $2.7B to $2.7B | $5.16 | $5.08 to $5.28 | 6 |
| Q2 FY28 | $2.7B | $2.7B to $2.8B | $4.80 | $4.72 to $4.91 | 6 |
Peers
Companies in Insurance - Brokers nearest Willis Towers Watson Public's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| WTWWillis Towers Watson Public | $30.2B | 19.9× | 26.0× | 15.5× | 3.0× | +3% | 15.5% |
| BROBrown & Brown | $23.6B | 21.1× | 29.1× | 15.2× | 3.5× | +34% | 17.7% |
| ERIEErie Indemnity | $14.3B | 24.8× | 31.6× | n/m | 3.5× | +4% | 14.0% |
| AONAon | $70.2B | 18.2× | 27.9× | 17.3× | 4.0× | +5% | 22.3% |
| AJGArthur J. Gallagher | $70.3B | 45.5× | 33.7× | 19.6× | 4.5× | +26% | 10.0% |
| RYANRyan Specialty | $11.6B | 63.2× | 92.2× | n/m | 3.6× | +14% | 3.1% |
| MRSHMarsh & McLennan Companies | $97.1B | 24.5× | 27.2× | 18.2× | 3.4× | +8% | 14.2% |
| ACTEnact | $6.6B | 10.1× | 7.8× | n/m | 5.3× | +2% | 54.5% |
| HGTYHagerty | $5.5B | 265× | 51.3× | n/m | 3.8× | +8% | 1.8% |
| CRVLCorvel | $4.2B | 37.0× | 38.1× | n/m | 4.3× | +7% | 11.7% |
| NPNeptune Insurance | $4.1B | 94.7× | 119× | n/m | 20.6× | +34% | 22.7% |
| Peer median | $13B | 30.9× | 32.6× | 17.7× | 3.9× | +8% | 14.1% |
Investors who own it
Investors we follow who held Willis Towers Watson Public at the end of Jun 30, 2026, from their 13F filings.
- Bill NygrenHarris Associates (Oakmark)2.1% of portfoliotrimmed
- Ron BaronBaron Capital0.0% of portfoliotrimmed
- Polen CapitalPolen Capital0.0% of portfoliotrimmed
More on Willis Towers Watson Public
Each number over time
- PE ratio
- Forward PE
- Price to sales ratio
- EV/EBIT
- Price to free cash flow
- Price to book ratio
- Dividend yield
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Where it ranks
- #3of 14Insurance brokers with the lowest PE ratio
- #4of 14Insurance brokers with the highest free cash flow yield
- #5of 17Insurance brokers with the highest profit margins
- #5of 15Insurance brokers with the lowest EV/EBIT
- #8of 21Insurance brokers with the lowest price to sales ratio
Its groups
About
- Industry
- Insurance - Brokers
- Sector
- Financial Services
Valuation data, not investment advice. Prices as of .